Table 1 Detailed characteristics of the included studies
Study | Year | Condition of disease | Length of treatment (weeks) | Number of participants (intervention/placebo) | Mean age | Male (%) | Dose of mavacamten |
|---|---|---|---|---|---|---|---|
Ho et al. [14] | 2020 | Non-HOCM | 24 | 40/19 | 53.9 | 42.4 | 200–500 ng/mL plasma concentration |
Olivotto et al. [15] | 2020 | HOCM | 30 | 123/128 | 58.5 | 59.3 | 350–700 ng/mL plasma concentration |
Saberi et al. [16] | 2020 | HOCM | 30 | 17/18 | 60.3 | 57.1 | 350–700 ng/mL plasma concentration |
Spertus et al. [17] | 2021 | HOCM | 30 | 98/96 | 57.9 | 60.8 | 350–700 ng/mL plasma concentration |